{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:10:14Z","timestamp":1785150614154,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2022R1A2C004822"],"award-info":[{"award-number":["NRF-2022R1A2C004822"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BK21 FOUR"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-91753-y","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T07:21:26Z","timestamp":1740986486000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of nationwide adverse event reports on Isoniazid and Rifampin in tuberculosis prevention and treatment in South Korea"],"prefix":"10.1038","volume":"15","author":[{"given":"Juhee","family":"Ryu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugyeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Won","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"91753_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12889-023-17495-6","volume":"24","author":"W Bai","year":"2024","unstructured":"Bai, W. & Ameyaw, E. K. Global, regional and National trends in tuberculosis incidence and main risk factors: a study using data from 2000 to 2021. BMC Public. Health. 24, 12. https:\/\/doi.org\/10.1186\/s12889-023-17495-6 (2024).","journal-title":"BMC Public. Health"},{"key":"91753_CR2","doi-asserted-by":"publisher","first-page":"1332211","DOI":"10.3389\/fcimb.2024.1332211","volume":"14","author":"P Zhu","year":"2024","unstructured":"Zhu, P. et al. Incidence and risk factors of active tuberculosis among older individuals with latent tuberculosis infection: a cohort study in two high-epidemic sites in Eastern China. Front. Cell. Infect. Microbiol. 14, 1332211. https:\/\/doi.org\/10.3389\/fcimb.2024.1332211 (2024).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"91753_CR3","doi-asserted-by":"publisher","first-page":"7604","DOI":"10.1038\/s41467-024-52122-x","volume":"15","author":"V Nduba","year":"2024","unstructured":"Nduba, V. et al. Mycobacterium tuberculosis cough aerosol culture status associates with host characteristics and inflammatory profiles. Nat. Commun. 15, 7604. https:\/\/doi.org\/10.1038\/s41467-024-52122-x (2024).","journal-title":"Nat. Commun."},{"key":"91753_CR4","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/s0140-6736(03)14333-4","volume":"362","author":"TR Frieden","year":"2003","unstructured":"Frieden, T. R., Sterling, T. R., Munsiff, S. S., Watt, C. J. & Dye, C. Tuberculosis Lancet 362, 887\u2013899, doi:https:\/\/doi.org\/10.1016\/s0140-6736(03)14333-4 (2003).","journal-title":"Tuberculosis Lancet"},{"key":"91753_CR5","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1164\/rccm.202011-4239PP","volume":"204","author":"MA Behr","year":"2021","unstructured":"Behr, M. A., Kaufmann, E., Duffin, J., Edelstein, P. H. & Ramakrishnan, L. Latent tuberculosis: two centuries of confusion. Am. J. Respir Crit. Care Med. 204, 142\u2013148. https:\/\/doi.org\/10.1164\/rccm.202011-4239PP (2021).","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"91753_CR6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jmii.2013.03.005","volume":"47","author":"X Xie","year":"2014","unstructured":"Xie, X., Li, F., Chen, J. W. & Wang, J. Risk of tuberculosis infection in anti-TNF-alpha biological therapy: from bench to bedside. J. Microbiol. Immunol. Infect. 47, 268\u2013274. https:\/\/doi.org\/10.1016\/j.jmii.2013.03.005 (2014).","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"91753_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/s2213-2600(19)30418-7","volume":"8","author":"E Harding","year":"2020","unstructured":"Harding, E. WHO global progress report on tuberculosis elimination. Lancet Respir Med. 8, 19. https:\/\/doi.org\/10.1016\/s2213-2600(19)30418-7 (2020).","journal-title":"Lancet Respir Med."},{"key":"91753_CR8","doi-asserted-by":"publisher","first-page":"e0255727","DOI":"10.1371\/journal.pone.0255727","volume":"16","author":"C Im","year":"2021","unstructured":"Im, C. & Kim, Y. Spatial pattern of tuberculosis (TB) and related socio-environmental factors in South Korea, 2008\u20132016. PLoS One. 16, e0255727. https:\/\/doi.org\/10.1371\/journal.pone.0255727 (2021).","journal-title":"PLoS One"},{"key":"91753_CR9","doi-asserted-by":"publisher","first-page":"e2018036","DOI":"10.4178\/epih.e2018036","volume":"40","author":"KS Cho","year":"2018","unstructured":"Cho, K. S. Tuberculosis control in the Republic of Korea. Epidemiol. Health. 40, e2018036. https:\/\/doi.org\/10.4178\/epih.e2018036 (2018).","journal-title":"Epidemiol. Health"},{"key":"91753_CR10","doi-asserted-by":"publisher","first-page":"106961","DOI":"10.1016\/j.ijid.2024.02.004","volume":"141","author":"J Lee","year":"2024","unstructured":"Lee, J., Kim, D., Hwang, J. & Kwon, J. W. Incidence of tuberculosis disease in individuals diagnosed with tuberculosis infection after screening: A population-based cohort study in South Korea. Int. J. Infect. Dis. 141, 106961. https:\/\/doi.org\/10.1016\/j.ijid.2024.02.004 (2024).","journal-title":"Int. J. Infect. Dis."},{"key":"91753_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","volume":"69","author":"TR Sterling","year":"2020","unstructured":"Sterling, T. R. et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National tuberculosis controllers association and CDC, 2020. MMWR Recomm Rep. 69, 1\u201311. https:\/\/doi.org\/10.15585\/mmwr.rr6901a1 (2020).","journal-title":"MMWR Recomm Rep."},{"key":"91753_CR12","doi-asserted-by":"publisher","first-page":"204209862093859","DOI":"10.1177\/2042098620938595","volume":"11","author":"M Alomar","year":"2020","unstructured":"Alomar, M., Tawfiq, A. M., Hassan, N. & Palaian, S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Ther. Adv. Drug Saf. 11, 2042098620938595. https:\/\/doi.org\/10.1177\/2042098620938595 (2020).","journal-title":"Ther. Adv. Drug Saf."},{"key":"91753_CR13","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1183\/09031936.00180612","volume":"42","author":"AS Albanna","year":"2013","unstructured":"Albanna, A. S., Smith, B. M., Cowan, D. & Menzies, D. Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis. Eur. Respir J. 42, 721\u2013732. https:\/\/doi.org\/10.1183\/09031936.00180612 (2013).","journal-title":"Eur. Respir J."},{"key":"91753_CR14","doi-asserted-by":"publisher","unstructured":"Gallardo, C. R. et al. Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis. Cochrane Database Syst Rev CD009913, (2016). https:\/\/doi.org\/10.1002\/14651858.CD009913.pub2 (2016).","DOI":"10.1002\/14651858.CD009913.pub2"},{"key":"91753_CR15","doi-asserted-by":"publisher","first-page":"11275","DOI":"10.1038\/s41598-023-38394-1","volume":"13","author":"HJ Kim","year":"2023","unstructured":"Kim, H. J. et al. Real-world experience of adverse reactions-necessitated rifampicin-sparing treatment for drug-susceptible pulmonary tuberculosis. Sci. Rep. 13, 11275. https:\/\/doi.org\/10.1038\/s41598-023-38394-1 (2023).","journal-title":"Sci. Rep."},{"key":"91753_CR16","doi-asserted-by":"publisher","first-page":"6826","DOI":"10.1038\/s41598-023-33967-6","volume":"13","author":"M Yagi","year":"2023","unstructured":"Yagi, M. et al. Factors associated with adverse drug reactions or death in very elderly hospitalized patients with pulmonary tuberculosis. Sci. Rep. 13, 6826. https:\/\/doi.org\/10.1038\/s41598-023-33967-6 (2023).","journal-title":"Sci. Rep."},{"key":"91753_CR17","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.3346\/jkms.2022.37.e128","volume":"37","author":"SJ Chung","year":"2022","unstructured":"Chung, S. J., Byeon, S. J. & Choi, J. H. Analysis of adverse drug reactions to First-Line Anti-Tuberculosis drugs using the Korea adverse event reporting system. J. Korean Med. Sci. 37, e128. https:\/\/doi.org\/10.3346\/jkms.2022.37.e128 (2022).","journal-title":"J. Korean Med. Sci."},{"key":"91753_CR18","doi-asserted-by":"publisher","first-page":"e0236109","DOI":"10.1371\/journal.pone.0236109","volume":"15","author":"BS Kwon","year":"2020","unstructured":"Kwon, B. S. et al. The high incidence of severe adverse events due to Pyrazinamide in elderly patients with tuberculosis. PLoS One. 15, e0236109. https:\/\/doi.org\/10.1371\/journal.pone.0236109 (2020).","journal-title":"PLoS One"},{"key":"91753_CR19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.2165\/00002018-199411040-00003","volume":"11","author":"JM Grange","year":"1994","unstructured":"Grange, J. M., Winstanley, P. A. & Davies, P. D. Clinically significant drug interactions with antituberculosis agents. Drug Saf. 11, 242\u2013251. https:\/\/doi.org\/10.2165\/00002018-199411040-00003 (1994).","journal-title":"Drug Saf."},{"key":"91753_CR20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa1714283","volume":"379","author":"D Menzies","year":"2018","unstructured":"Menzies, D. et al. Four months of Rifampin or nine months of Isoniazid for latent tuberculosis in adults. N Engl. J. Med. 379, 440\u2013453. https:\/\/doi.org\/10.1056\/NEJMoa1714283 (2018).","journal-title":"N Engl. J. Med."},{"key":"91753_CR21","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1093\/cid\/ciw126","volume":"62","author":"RN Moro","year":"2016","unstructured":"Moro, R. N. et al. Factors associated with noncompletion of latent tuberculosis infection treatment: experience from the PREVENT TB trial in the united States and Canada. Clin. Infect. Dis. 62, 1390\u20131400. https:\/\/doi.org\/10.1093\/cid\/ciw126 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"91753_CR22","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.ccm.2019.07.008","volume":"40","author":"MA Huaman","year":"2019","unstructured":"Huaman, M. A. & Sterling, T. R. Treatment of latent tuberculosis Infection-An update. Clin. Chest Med. 40, 839\u2013848. https:\/\/doi.org\/10.1016\/j.ccm.2019.07.008 (2019).","journal-title":"Clin. Chest Med."},{"key":"91753_CR23","unstructured":"Korean Guidelines For Tuberculosis. (Korea Centers for Disease Control and Prevention, (2024)."},{"key":"91753_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/1715163516641136","volume":"149","author":"JE Tisdale","year":"2016","unstructured":"Tisdale, J. E. Drug-induced QT interval prolongation and Torsades de pointes: role of the pharmacist in risk assessment, prevention and management. Can. Pharm. J. (Ott). 149, 139\u2013152. https:\/\/doi.org\/10.1177\/1715163516641136 (2016).","journal-title":"Can. Pharm. J. (Ott)"},{"key":"91753_CR25","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1136\/postgradmedj-2020-138661","volume":"97","author":"R Khatib","year":"2021","unstructured":"Khatib, R., Sabir, F. R. N., Omari, C., Pepper, C. & Tayebjee, M. H. Managing drug-induced QT prolongation in clinical practice. Postgrad. Med. J. 97, 452\u2013458. https:\/\/doi.org\/10.1136\/postgradmedj-2020-138661 (2021).","journal-title":"Postgrad. Med. J."},{"key":"91753_CR26","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2217\/pgs-2022-0027","volume":"23","author":"AI Lopez-Medina","year":"2022","unstructured":"Lopez-Medina, A. I., Chahal, C. A. A. & Luzum, J. A. The genetics of drug-induced QT prolongation: evaluating the evidence for pharmacodynamic variants. Pharmacogenomics 23, 543\u2013557. https:\/\/doi.org\/10.2217\/pgs-2022-0027 (2022).","journal-title":"Pharmacogenomics"},{"key":"91753_CR27","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1001\/jama.289.16.2120","volume":"289","author":"SM Al-Khatib","year":"2003","unstructured":"Al-Khatib, S. M., LaPointe, N. M., Kramer, J. M. & Califf, R. M. What clinicians should know about the QT interval. Jama 289, 2120\u20132127. https:\/\/doi.org\/10.1001\/jama.289.16.2120 (2003).","journal-title":"Jama"},{"key":"91753_CR28","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1056\/NEJMoa1507062","volume":"374","author":"AD Heemskerk","year":"2016","unstructured":"Heemskerk, A. D. et al. Intensified antituberculosis therapy in adults with tuberculous meningitis. N Engl. J. Med. 374, 124\u2013134. https:\/\/doi.org\/10.1056\/NEJMoa1507062 (2016).","journal-title":"N Engl. J. Med."},{"key":"91753_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40794-023-00205-w","volume":"9","author":"JKS Tsui","year":"2023","unstructured":"Tsui, J. K. S., Poon, S. H. L. & Fung, N. S. K. Ocular manifestations and diagnosis of tuberculosis involving the Uvea: a case series. Trop. Dis. Travel Med. Vaccines. 9, 20. https:\/\/doi.org\/10.1186\/s40794-023-00205-w (2023).","journal-title":"Trop. Dis. Travel Med. Vaccines"},{"key":"91753_CR30","first-page":"438","volume":"3","author":"SB Kokkada","year":"2005","unstructured":"Kokkada, S. B. et al. Ocular side effects of antitubercular drugs - a focus on prevention, early detection and management. Kathmandu Univ. Med. J. (KUMJ). 3, 438\u2013441 (2005).","journal-title":"Kathmandu Univ. Med. J. (KUMJ)"},{"key":"91753_CR31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4103\/0974-9233.51996","volume":"15","author":"EE Egbagbe","year":"2008","unstructured":"Egbagbe, E. E. & Omoti, A. E. Ocular disorders in adult patients with tuberculosis in a tertiary care hospital in Nigeria. Middle East. Afr. J. Ophthalmol. 15, 73\u201376. https:\/\/doi.org\/10.4103\/0974-9233.51996 (2008).","journal-title":"Middle East. Afr. J. Ophthalmol."},{"key":"91753_CR32","doi-asserted-by":"publisher","first-page":"102056","DOI":"10.1016\/j.pupt.2021.102056","volume":"70","author":"N Laohapojanart","year":"2021","unstructured":"Laohapojanart, N., Ratanajamit, C., Kawkitinarong, K. & Srichana, T. Efficacy and safety of combined isoniazid-rifampicin-pyrazinamide-levofloxacin dry powder inhaler in treatment of pulmonary tuberculosis: A randomized controlled trial. Pulm Pharmacol. Ther. 70, 102056. https:\/\/doi.org\/10.1016\/j.pupt.2021.102056 (2021).","journal-title":"Pulm Pharmacol. Ther."},{"key":"91753_CR33","doi-asserted-by":"publisher","first-page":"e37399","DOI":"10.7759\/cureus.37399","volume":"15","author":"D Kong","year":"2023","unstructured":"Kong, D. et al. Drug reaction with eosinophilia and systemic Symptoms-Associated perimyocarditis after initiation of Anti-tuberculosis therapy: A case report. Cureus 15, e37399. https:\/\/doi.org\/10.7759\/cureus.37399 (2023).","journal-title":"Cureus"},{"key":"91753_CR34","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.clindermatol.2016.10.007","volume":"35","author":"J Kazandjieva","year":"2017","unstructured":"Kazandjieva, J. & Tsankov, N. Drug-induced acne. Clin. Dermatol. 35, 156\u2013162. https:\/\/doi.org\/10.1016\/j.clindermatol.2016.10.007 (2017).","journal-title":"Clin. Dermatol."},{"key":"91753_CR35","first-page":"26","volume":"61","author":"RP Sharma","year":"1995","unstructured":"Sharma, R. P., Kothari, A. K. & Sharma, N. K. Acneform eruptions and antitubercular drugs. Indian J. Dermatol. Venereol. Leprol. 61, 26\u201327 (1995).","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"91753_CR36","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/bcp.12885","volume":"81","author":"I Metushi","year":"2016","unstructured":"Metushi, I., Uetrecht, J. & Phillips, E. Mechanism of isoniazid-induced hepatotoxicity: then and now. Br. J. Clin. Pharmacol. 81, 1030\u20131036. https:\/\/doi.org\/10.1111\/bcp.12885 (2016).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"91753_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1185\/03007995.2012.747952","volume":"29","author":"AM Baciewicz","year":"2013","unstructured":"Baciewicz, A. M., Chrisman, C. R., Finch, C. K. & Self, T. H. Update on Rifampin, Rifabutin, and rifapentine drug interactions. Curr. Med. Res. Opin. 29, 1\u201312. https:\/\/doi.org\/10.1185\/03007995.2012.747952 (2013).","journal-title":"Curr. Med. Res. Opin."},{"key":"91753_CR38","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jaad.2023.12.017","volume":"90","author":"RV Reynolds","year":"2024","unstructured":"Reynolds, R. V. et al. Guidelines of care for the management of acne vulgaris. J. Am. Acad. Dermatol. 90, 1006. .e1001-1006.e1030 (2024).","journal-title":"J. Am. Acad. Dermatol."},{"key":"91753_CR39","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","volume":"43","author":"O Caster","year":"2020","unstructured":"Caster, O., Aoki, Y., Gattepaille, L. M. & Grundmark, B. Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting False-Positive associations. Drug Saf. 43, 479\u2013487. https:\/\/doi.org\/10.1007\/s40264-020-00911-w (2020).","journal-title":"Drug Saf."},{"key":"91753_CR40","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1136\/bmj.316.7139.1236","volume":"316","author":"TV Perneger","year":"1998","unstructured":"Perneger, T. V. What\u2019s wrong with bonferroni adjustments. Bmj 316, 1236\u20131238. https:\/\/doi.org\/10.1136\/bmj.316.7139.1236 (1998).","journal-title":"Bmj"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91753-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91753-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91753-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T11:59:28Z","timestamp":1741348768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91753-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["91753"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-91753-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"assertion":[{"value":"8 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7411"}}